Firmer evidence to support Assembly’s approach to vanquishing the hepatitis B virus will not emerge until next year, and rivals are not standing still in the meantime.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
Tucatinib yields a positive result in breast cancer, vindicating Seattle Genetics’ acquisition of its originator.
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
In liver cancer Roche hopes to succeed where Bristol failed, while Incyte tests its Jakafi follow-on in first-line graft-versus-host disease.